Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/druginfo/natural/1264.html

Green Coffee

What is it?

Green coffee is unroasted coffee beans from Coffea fruits (Coffea arabica, Coffea canephora). It contains more chlorogenic acid than roasted coffee.

The chlorogenic acid in green coffee is thought to have health benefits. It might affect blood vessels so that blood pressure is reduced. It might also affect how the body handles blood sugar and metabolism. Green coffee also contains caffeine, but in lower amounts than regular coffee.

People take green coffee for obesity, diabetes, high blood pressure, high cholesterol, and many other conditions, but there is no good scientific evidence to support these uses.

Don't confuse green coffee with other caffeine sources, including coffee, black tea, and green tea. These are not the same.

How effective is it?

There is interest in using green coffee for a number of purposes, but there isn't enough reliable information to say whether it might be helpful.

Is it safe?

When taken by mouth: Green coffee is possibly safe when used appropriately. Green coffee extracts taken in doses up to 1000 mg daily have been used safely for up to 12 weeks. A specific green coffee extract (Svetol, Naturex) has been used safely in doses up to 200 mg five times daily for up to 12 weeks.

Green coffee contains caffeine, but in lower amounts than in regular coffee. One cup of green coffee contains about 25-50% of the amount of caffeine found in a one cup of regular coffee. Consuming large amounts of green coffee might cause caffeine-related side effects, including headache, anxiety, agitation, and irregular heartbeat.

Special precautions & warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if green coffee is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Abnormally high levels of homocysteine: Consuming a high dose of chlorogenic acid might increase homocysteine levels, which might be linked to conditions such as heart disease.

Anxiety disorders: The caffeine in green coffee might make anxiety worse.

Bleeding disorders: The caffeine in green coffee might make bleeding disorders worse.

Diabetes: The caffeine in green coffee might affect the way people with diabetes process sugar. Use caffeine with caution if you have diabetes and monitor your blood sugar carefully.

Diarrhea: Green coffee contains caffeine. Caffeine, especially when taken in large amounts, can worsen diarrhea.

Epilepsy: Green coffee contains caffeine. People with epilepsy should avoid using caffeine in high doses. Low doses of caffeine should be used cautiously.

Glaucoma: The caffeine in green coffee can increase pressure inside the eye, which can make glaucoma worse.

High blood pressure: The caffeine in green coffee might increase blood pressure in people with high blood pressure. But this effect might be less in people who consume caffeine regularly.

Irritable bowel syndrome (IBS): Green coffee contains caffeine. Caffeine, especially when taken in large amounts, might worsen the diarrhea some people have with IBS.

Osteoporosis: Caffeine from green coffee and other sources can increase the amount of calcium that is flushed out in the urine. This might weaken bones. If you have osteoporosis, limit caffeine consumption to less than 300 mg per day.

Are there interactions with medications?

Major
Do not take this combination.
Ephedrine
Stimulant drugs speed up the nervous system. The caffeine in green coffee and ephedrine are both stimulant drugs. Taking green coffee and ephedrine might cause too much stimulation and sometimes serious side effects and heart problems. Do not take caffeine-containing products and ephedrine at the same time.
Moderate
Be cautious with this combination.
Adenosine (Adenocard)
Green coffee contains caffeine. The caffeine in green coffee might block the effects of adenosine, which is often used by doctors to do a test called a cardiac stress test. Stop consuming green coffee at least 24 hours before a cardiac stress test.
Alendronate (Fosamax)
Green coffee might decrease how much alendronate the body absorbs. Taking green coffee and alendronate at the same time might decrease the effects of alendronate. Don't take green coffee within two hours of taking alendronate.
Birth control pills (Contraceptive drugs)
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Birth control pills can decrease how quickly the body breaks down caffeine. This might increase the risk for side effects from caffeine, such as jitteriness, headache, and fast heartbeat.
Cimetidine (Tagamet)
The body breaks down the caffeine in green coffee to get rid of it. Cimetidine can decrease how quickly your body breaks down caffeine. Taking cimetidine along with green coffee might increase the chance of caffeine side effects including jitteriness, headache, fast heartbeat, and others.
Clozapine (Clozaril)
The body breaks down clozapine to get rid of it. The caffeine in green coffee might decrease how fast the body breaks down clozapine. Taking green coffee along with clozapine can increase the effects and side effects of clozapine.
Dipyridamole (Persantine)
The caffeine in green coffee might block the effects of dipyridamole. Dipyridamole is often used by doctors to do a test on the heart called a cardiac stress test. Stop taking green coffee at least 24 hours before a cardiac stress test.
Disulfiram (Antabuse)
The body breaks down the caffeine in green coffee to get rid of it. Disulfiram can decrease how quickly the body gets rid of caffeine. Taking green coffee along with disulfiram might increase the side effects of caffeine including jitteriness, hyperactivity, irritability, and others.
Estrogens
The body breaks down the caffeine in green coffee to get rid of it. Estrogens can decrease how quickly the body breaks down caffeine. Taking estrogen and green coffee might increase caffeine side effects, including jitteriness, headache, fast heartbeat, and others. If you take estrogen, limit your caffeine intake.
Fluvoxamine (Luvox)
The body breaks down the caffeine in green coffee to get rid of it. Fluvoxamine can decrease how quickly the body breaks down caffeine. Taking caffeine along with fluvoxamine might increase caffeine side effects including nervousness, anxiety, and insomnia.
Lithium
Green coffee contains caffeine. Caffeine can increase how quickly your body gets rid of lithium. If you take products that contain caffeine and you take lithium, don't stop taking caffeine products all at once. Instead, reduce use slowly. Stopping caffeine too quickly can increase the side effects of lithium.
Medications for asthma (Beta-adrenergic agonists)
Green coffee contains caffeine. Caffeine can stimulate the heart. Some medications for asthma can also stimulate the heart. Taking caffeine with some medications for asthma might cause too much stimulation and cause heart problems.
Medications for depression (MAOIs)
Green coffee contains caffeine. There is some concern that caffeine can interact with certain medications, called MAOIs. If caffeine is taken with these medications, it might increase the risk of serious side effects including fast heartbeat and very high blood pressure.

Some common MAOIs include phenelzine (Nardil), selegiline (Zelapar), and tranylcypromine (Parnate).
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)
Green coffee might slow blood clotting. Taking green coffee along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
Nicotine
Green coffee contains caffeine. Taking caffeine along with nicotine might increase rapid heart rate and blood pressure.
Pentobarbital (Nembutal)
Green coffee contains caffeine. The stimulant effects of caffeine can block the sleep-producing effects of pentobarbital.
Phenylpropanolamine
The caffeine in green coffee can stimulate the body. Phenylpropanolamine can also stimulate the body. Taking caffeine and phenylpropanolamine together might cause too much stimulation and increase heartbeat, blood pressure, and cause nervousness.
Pioglitazone (Actos)
Green coffee contains caffeine. Caffeine might increase the amount of pioglitazone that the body absorbs. Taking green coffee might increase the effects and adverse effects of pioglitazone.
Riluzole (Rilutek)
Green coffee can decrease how quickly the body breaks down riluzole and increase the effects and side effects of riluzole.
Stimulant drugs
Stimulants, such as amphetamines and cocaine, speed up the nervous system. By speeding up the nervous system, stimulant medications can increase blood pressure and speed up the heartbeat. Green coffee contains caffeine. Caffeine can also speed up the nervous system. Taking green coffee along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure.
Theophylline
The caffeine in green coffee works similarly to theophylline. Caffeine can also decrease how quickly the body gets rid of theophylline. Taking green coffee and taking theophylline might increase the effects and side effects of theophylline.
Verapamil (Calan, others)
Verapamil can decrease how quickly the body gets rid of caffeine. Drinking green coffee and taking verapamil can increase the risk of caffeine side effects including jitteriness, headache, and an increased heartbeat.
Water pills (Diuretic drugs)
The caffeine in green coffee can reduce potassium levels. "Water pills" can also decrease potassium levels in the body. Taking caffeine with water pills might cause potassium levels to drop too low.
Some "water pills" that can deplete potassium include chlorothiazide (Diuril), chlorthalidone (Thalitone), furosemide (Lasix), hydrochlorothiazide (HCTZ, HydroDiuril, Microzide), and others.
Minor
Be watchful with this combination.
Alcohol (Ethanol)
The body breaks down the caffeine in green coffee to get rid of it. Alcohol can decrease how quickly the body breaks down caffeine. Taking green coffee along with alcohol might increase the risk for caffeine side effects including jitteriness, headache, and fast heartbeat.
Antibiotics (Quinolone antibiotics)
The body breaks down caffeine to get rid of it. Some antibiotics might decrease how quickly the body breaks down caffeine. Taking these antibiotics along with green coffee can increase the risk of caffeine side effects including jitteriness, headache, increased heart rate, and others.
Fluconazole (Diflucan)
The body breaks down the caffeine in green coffee to get rid of it. Fluconazole might decrease how quickly the body gets rid of caffeine. Taking fluconazole and green coffee might increase caffeine side effects including nervousness, anxiety, and insomnia.
Medications for diabetes (Antidiabetes drugs)
Green coffee might increase or decrease blood sugar levels. Taking green coffee along with diabetes medications might change the effects of these medications. Monitor your blood sugar closely.
Medications for high blood pressure (Antihypertensive drugs)
Green coffee might lower blood pressure. Taking green coffee along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.
Mexiletine (Mexitil)
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Mexiletine can decrease how quickly the body breaks down caffeine. Taking mexiletine along with green coffee might increase the risk of caffeine side effects.
Phenothiazines
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Phenothiazines can decrease how quickly the body breaks down caffeine. Taking phenothiazines along with green coffee might increase the risk of caffeine side effects.
Terbinafine (Lamisil)
The body breaks down the caffeine in green coffee to get rid of it. Terbinafine can decrease how fast the body gets rid of caffeine. This might increase the risk of caffeine side effects including jitteriness, headache, increased heartbeat, and others.

Are there interactions with herbs and supplements?

Bitter orange
Green coffee contains caffeine. Bitter orange, used along with caffeine or caffeine-containing herbs such as green coffee, can increase blood pressure and heart rate in otherwise healthy people. This might damage the heart and blood vessels.
Caffeine-containing herbs and supplements
Green coffee contains caffeine. Taking it along with other products that contain caffeine might increase caffeine side effects. Examples of supplements that contain caffeine include black tea, coffee, green tea, guarana, and yerba mate.
Calcium
Green coffee contains caffeine. High doses of caffeine can increase the loss of calcium in the urine.
Cordyceps
Green coffee contains caffeine. Cordyceps might increase how quickly the body gets rid of caffeine. This might decrease the effects of caffeine.
Creatine
Green coffee contains caffeine. There is some concern that combining caffeine or caffeine-containing beverages and herbs with ephedra and creatine might increase the risk of serious side effects. There is a report of stroke in one athlete who used creatine monohydrate, caffeine, ephedra, and a variety of other supplements daily for 6 weeks. Caffeine might also decrease creatine's possible beneficial effects on athletic performance.
Cyclodextrin
Cyclodextrin is a dietary fiber. It might bind with a chemical found in green coffee, called chlorogenic acid. This might reduce the blood pressure-lowering effects of green coffee.
Echinacea
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Echinacea might decrease how quickly the body breaks down caffeine. Using echinacea with caffeine might increase caffeine levels.
Ephedra (Ma huang)
Don't take green coffee with ephedra. Using ephedra with the caffeine in green coffee might increase the risk of serious life-threatening or disabling conditions such as hypertension, heart attack, stroke, seizures, and death.
Genistein-containing herbs and supplements
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Taking herbs or supplements that contain genistein might decrease how quickly the body breaks down caffeine. Using genistein with caffeine might increase caffeine levels.
Herbs and supplements that might lower blood pressure
Green coffee might lower blood pressure. Taking it with other supplements that have the same effect might cause blood pressure to drop too much. Examples of supplements with this effect include andrographis, casein peptides, L-arginine, niacin, and stinging nettle.
Herbs and supplements that might lower blood sugar
Green coffee might lower blood sugar. Taking it with other supplements with similar effects might lower blood sugar too much. Examples of supplements with this effect include aloe, bitter melon, cassia cinnamon, chromium, and prickly pear cactus.
Herbs and supplements that might slow blood clotting
Green coffee might slow blood clotting and increase the risk of bleeding. Taking it with other supplements with similar effects might increase the risk of bleeding in some people. Examples of supplements with this effect include garlic, ginger, ginkgo, nattokinase, and Panax ginseng.
Iron
Certain components of green coffee might reduce the amount of iron the body absorbs from food.
Kudzu
Green coffee contains caffeine. The body breaks down caffeine to get rid of it. Kudzu seems to decrease how quickly the body breaks down caffeine. Using kudzu with caffeine might increase caffeine levels.
Magnesium
Green coffee contains caffeine. High doses of caffeine can increase how quickly the body releases magnesium in the urine.
Melatonin
Green coffee contains caffeine. Taking caffeine and melatonin together can increase melatonin levels.

Are there interactions with foods?

There are no known interactions with foods.

How is it typically used?

Green coffee extract has most often been used by adults in doses of 90-1000 mg by mouth daily for 8-12 weeks. Speak with a healthcare provider to find out what dose might be best for a specific condition.

Keep in mind that green coffee contains caffeine, but in lower amounts than in regular coffee. When coffee beans are roasted, they release water and the caffeine in the bean is more readily released when brewed. Unroasted (green) coffee beans release less caffeine when brewed. One cup of green coffee contains about 20-50 mg of caffeine, compared to about 100 mg in one cup of regular coffee.

Other names

Arabica Green Coffee Beans, Café Marchand, Café Verde, Café Vert, Coffea arabica, Coffea arnoldiana, Coffea bukobensis, Coffea canephora, Coffea liberica, Coffea robusta, Extrait de Café Vert, Extrait de Fève de Café Vert, Fèves de Café Vert, Fèves de Café Vert Arabica, Fèves de Café Vert Robusta, GCBE, GCE, Green Coffee Beans, Green Coffee Bean Extract, Green Coffee Extract, Green Coffee Powder, Poudre de Café Vert, Raw Coffee, Raw Coffee Extract, Robusta Green Coffee Beans, Svetol.

Methodology

To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.

References

  1. Chen Y, Zhao Y, Wang Y, et al. The influence of green coffee bean extract supplementation on blood glucose levels: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytother Res. 2020;34:2159-2169. View abstract.
  2. Ding F, Ma B, Nazary-Vannani A, et al. The effects of green coffee bean extract supplementation on lipid profile in humans: A systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2020;30:1-10. View abstract.
  3. Meshkani M, Saedisomeolia A, Yekaninejad M, Mousavi SA, Ildarabadi A, Vahid-Dastjerdi M. The effect of green coffee supplementation on lipid profile, glycemic indices, inflammatory biomarkers and anthropometric indices in Iranian women with polycystic ovary syndrome: A randomized clinical trial. Clin Nutr Res 2022;11:241-254. View abstract.
  4. Bahmannia M, Azizzade M, Heydari S, et al. Effects of decaffeinated green coffee extract supplementation on anthropometric indices, blood glucose, leptin, adiponectin and neuropeptide Y (NPY) in breast cancer survivors: a randomized clinical trial. Food Funct 2022;13:10347-10356. View abstract.
  5. García-Cordero J, Sierra-Cinos JL, Seguido MA, et al. Regular consumption of green coffee phenol, oat ß-glucan and green coffee phenol/oat ß-glucan supplements does not change body composition in subjects with overweight and obesity. Foods 2022;11:679. View abstract.
  6. Alshabi AM, Alkahtani SA, Shaikh IA, Habeeb MS. Caffeine modulates pharmacokinetic and pharmacodynamic profiles of pioglitazone in diabetic rats: Impact on therapeutics. Saudi Med J 2021;42:151-160. View abstract.
  7. Wang S, Li X, Yang Y, et al. Does coffee, tea and caffeine consumption reduce the risk of incident breast cancer? A systematic review and network meta-analysis. Public Health Nutr 2021;24:6377-6389. View abstract.
  8. Zheng KH, Zhu K, Wactawski-Wende J, et al. Caffeine intake from coffee and tea and invasive breast cancer incidence among postmenopausal women in the Women's Health Initiative. Int J Cancer 2021;149:2032-2044. View abstract.
  9. Asbaghi O, Kashkooli S, Mardani M, et al. Effect of green coffee bean extract supplementation on liver function and inflammatory biomarkers: A meta-analysis of randomized clinical trials. Complement Ther Clin Pract 2021;43:101349. View abstract.
  10. Pourmasoumi M, Hadi A, Marx W, Najafgholizadeh A, Kaur S, Sahebkar A. The Effect of Green Coffee Bean Extract on Cardiovascular Risk Factors: A Systematic Review and Meta-analysis. Adv Exp Med Biol 2021;1328:323-345. View abstract.
  11. Weerakoon WNMTDN, Anjali NVP, Jayathilaka N, Seneviratne KN. Soybean oil and coconut oil enhance the absorption of chlorogenic acid in humans. J Food Biochem 2021;e13823. View abstract.
  12. Khaneghah AM, Fakhri Y, Abdi L, Coppa CFSC, Franco LT, de Oliveira CAF. The concentration and prevalence of ochratoxin A in coffee and coffee-based products: A global systematic review, meta-analysis and meta-regression. Fungal Biol. 2019;123:611-617. View abstract.
  13. Roshan H, Nikpayam O, Sedaghat M, Sohrab G. Effects of green coffee extract supplementation on anthropometric indices, glycaemic control, blood pressure, lipid profile, insulin resistance and appetite in patients with the metabolic syndrome: a randomised clinical trial. Br J Nutr. 2018;119:250-258. View abstract.
  14. Chen H, Huang W, Huang X, et al. Effects of green coffee bean extract on C-reactive protein levels: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2020;52:102498. View abstract.
  15. Twaruzek M, Kosicki R, Kwiatkowska-Gizynska J, Grajewski J, Altyn I. Ochratoxin A and citrinin in green coffee and dietary supplements with green coffee extract. Toxicon. 2020;188:172-177. View abstract.
  16. Nikpayam O, Najafi M, Ghaffari S, Jafarabadi MA, Sohrab G, Roshanravan N. Effects of green coffee extract on fasting blood glucose, insulin concentration and homeostatic model assessment of insulin resistance (HOMA-IR): a systematic review and meta-analysis of interventional studies. Diabetol Metab Syndr. 2019;11:91. View abstract.
  17. Martínez-López S, Sarriá B, Mateos R, Bravo-Clemente L. Moderate consumption of a soluble green/roasted coffee rich in caffeoylquinic acids reduces cardiovascular risk markers: results from a randomized, cross-over, controlled trial in healthy and hypercholesterolemic subjects. Eur J Nutr. 2019;58:865-878. View abstract.
  18. Asbaghi O, Sadeghian M, Rahmani S, et al. The effect of green coffee extract supplementation on anthropometric measures in adults: A comprehensive systematic review and dose-response meta-analysis of randomized clinical trials. Complement Ther Med. 2020;51:102424. View abstract.
  19. Li S, Dai Z, Wu Q. Effect of coffee intake on hip fracture: a meta-analysis of prospective cohort studies. Nutr J. 2015;14:38. View abstract.
  20. Lee DR, Lee J, Rota M, et al. Coffee consumption and risk of fractures: a systematic review and dose-response meta-analysis. Bone. 2014;63:20-8. View abstract.
  21. Cozma-Petrut A, Loghin F, Miere D, Dumitrascu DL.Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! World J Gastroenterol. 2017;23:3771-3783. View abstract.
  22. Rao SS. Current and emerging treatment options for fecal incontinence. J Clin Gastroenterol. 2014;48:752-64. View abstract.
  23. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol 2017;109:585-648. View abstract.
  24. Cappelletti S, Piacentino D, Fineschi V, Frati P, Cipollini L, Aromatario M. Caffeine-related deaths: manner of deaths and categories of risk. Nutrients. 2018 May 14;10. pii: E611. View abstract.
  25. Kunitake Y, Mizoguchi Y, Sogawa R, et al. Effect of excessive coffee consumption on the clinical course of a patient with bipolar disorder: a case report and literature review. Clin Neuropharmacol. 2017 Jul/Aug;40:160-162. doi: 10.1097/WNF.0000000000000222. View abstract.
  26. Magdalan J, Zawadzki M, Skowronek R, et al. Nonfatal and fata intoxications with pure caffeine - report of three different cases. Forensic Sci Med Pathol. 2017 Sep;13:355-58. View abstract.
  27. Tejani FH, Thompson RC, Kristy R, Bukofzer S. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. Int J Cardiovasc Imaging. 2014 Jun;30:979-89. doi: 10.1007/s10554-014-0419-7. Epub 2014 17. View abstract.
  28. Poussel M, Kimmoun A, Levy B, Gambier N, Dudek F, Puskarczyk E, Poussel JF, Chenuel B. Fatal cardiac arrhythmia following voluntary caffeine overdose in an amateur body-builder athlete. Int J Cardiol. 2013 1;166:e41-2. doi: 10.1016/j.ijcard.2013.01.238. Epub 2013 7. No abstract available. View abstract.
  29. Jabbar SB, Hanly MG. Fatal caffeine overdose: a case report and review of literature. Am J Forensic Med Pathol. 2013;34:321-4. doi: 10.1097/PAF.0000000000000058. Review. View abstract.
  30. Bonsignore A, Sblano S, Pozzi F, Ventura F, Dell'Erba A, Palmiere C. A case of suicide by ingestion of caffeine. Forensic Sci Med Pathol. 2014 Sep;10:448-51. doi: 10.1007/s12024-014-9571-6. Epub 2014 27. View abstract.
  31. Beaudoin MS, Allen B, Mazzetti G, Sullivan PJ, Graham TE. Caffeine ingestion impairs insulin sensitivity in a dose-dependent manner in both men and women. Appl Physiol Nutr Metab. 2013;38:140-7. doi: 10.1139/apnm-2012-0201. Epub 2012 9. View abstract.
  32. Svetol Product Information Pack. Naturex, Avignon, France. March 2013. Available at: http://greencoffee.gr/wp-content/uploads/2013/12/GA501071_PRODUCT-INFO-PACK_04-06-2013.pdf (accessed July 6, 2015).
  33. Vinson J, Burnham B. Retraction: Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes 2014;7:467. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC4206203/.
  34. Federal Trade Commission Press Release. Green coffee bean manufacturer settles FTC charges of pushing its product based on results of "seriously flawed" weight loss study. Available at: www.ftc.gov/news-events/press-releases/2014/09/green-coffee-bean-manufacturer-settles-ftc-charges-pushing-its (accessed July 5, 2015).
  35. Smits, P., Corstens, F. H., Aengevaeren, W. R., Wackers, F. J., and Thien, T. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl.Med. 1991;32:1538-1541. View abstract.
  36. Saito, T., Tsuchida, T., Watanabe, T., Arai, Y., Mitsui, Y., Okawa, W., and Kajihara, Y. Effect of coffee bean extract in essential hypertension. Jpn J Med Pharm Sci 2002;47:67-74.
  37. Blum, J., Lemaire, B., and Lafay, S. Effect of a green decaffeinated coffee extract on glycaemia: a pilot prospective study. Nutrafoods 2007;6:13-17.
  38. Dellalibera, O., Lemaire, B., and Lafay, S. Svetol®, green coffee extract, induces weight loss and increases the lean to fat mass ratio in volunteers with overweight problem. Phytotherapie 2006;4:1-4.
  39. Arion, W. J., Canfield, W. K., Ramos, F. C., Schindler, P. W., Burger, H. J., Hemmerle, H., Schubert, G., Below, P., and Herling, A. W. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch.Biochem.Biophys. 3-15-1997;339:315-322. View abstract.
  40. Mairesse, M., Casel, S., and Ledent, C. [Asthma to green coffee of environmental origin]. Rev.Mal Respir. 1996;13:308-309. View abstract.
  41. Peyresblanques, J. [Conjunctival allergy to green coffee]. Bull.Soc.Ophtalmol.Fr. 1984;84:1097-1098. View abstract.
  42. Franzke, C., Grunert, K. S., Hildebrandt, U., and Griehl, H. [On the theobromine and theophylline content of raw coffee and tea]. Pharmazie 9-9-1968;23:502-503. View abstract.
  43. Zuskin, E., Kanceljak, B., Skuric, Z., and Butkovic, D. Bronchial reactivity in green coffee exposure. Br.J.Ind.Med. 1985;42:415-420. View abstract.
  44. Zuskin, E., Dreshaj, I., Jakupi, M., and Haxhiu, M. A. Effect of exposure to green coffee dust extract on airway reactivity. Arh.Hig.Rada Toksikol. 1986;37:205-216. View abstract.
  45. Johansen, J. P. and Viskum, S. [Asthma associated with the handling of green coffee beans]. Ugeskr.Laeger 10-12-1987;149:2853. View abstract.
  46. Uragoda, C. G. Acute symptoms in coffee workers. J.Trop.Med.Hyg. 1988;91:169-172. View abstract.
  47. Zuskin, E., Kanceljak, B., Mataija, M., and Tonkovic-Lojovic, M. [Specific bronchial reactivity in unripe coffee processing workers]. Arh.Hig.Rada Toksikol. 1989;40:3-8. View abstract.
  48. Thomas, K. E., Trigg, C. J., Baxter, P. J., Topping, M., Lacey, J., Crook, B., Whitehead, P., Bennett, J. B., and Davies, R. J. Factors relating to the development of respiratory symptoms in coffee process workers. Br.J.Ind.Med. 1991;48:314-322. View abstract.
  49. Suzuki, A., Fujii, A., Jokura, H., Tokimitsu, I., Hase, T., and Saito, I. Hydroxyhydroquinone interferes with the chlorogenic acid-induced restoration of endothelial function in spontaneously hypertensive rats. Am.J.Hypertens. 2008;21:23-27. View abstract.
  50. Selmar, D., Bytof, G., and Knopp, S. E. The storage of green coffee (Coffea arabica): decrease of viability and changes of potential aroma precursors. Ann.Bot. 2008;101:31-38. View abstract.
  51. Oka, K. [Pharmacological bases of coffee nutrients for diabetes prevention]. Yakugaku Zasshi 2007;127:1825-1836. View abstract.
  52. Takahama, U., Ryu, K., and Hirota, S. Chlorogenic acid in coffee can prevent the formation of dinitrogen trioxide by scavenging nitrogen dioxide generated in the human oral cavity. J.Agric.Food Chem. 10-31-2007;55:9251-9258. View abstract.
  53. Monteiro, M., Farah, A., Perrone, D., Trugo, L. C., and Donangelo, C. Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans. J.Nutr. 2007;137:2196-2201. View abstract.
  54. Glei, M., Kirmse, A., Habermann, N., Persin, C., and Pool-Zobel, B. L. Bread enriched with green coffee extract has chemoprotective and antigenotoxic activities in human cells. Nutr.Cancer 2006;56:182-192. View abstract.
  55. Greenberg, J. A., Boozer, C. N., and Geliebter, A. Coffee, diabetes, and weight control. Am.J.Clin.Nutr. 2006;84:682-693. View abstract.
  56. Suzuki, A., Fujii, A., Yamamoto, N., Yamamoto, M., Ohminami, H., Kameyama, A., Shibuya, Y., Nishizawa, Y., Tokimitsu, I., and Saito, I. Improvement of hypertension and vascular dysfunction by hydroxyhydroquinone-free coffee in a genetic model of hypertension. FEBS Lett. 4-17-2006;580:2317-2322. View abstract.
  57. Higdon, J. V. and Frei, B. Coffee and health: a review of recent human research. Crit Rev.Food Sci.Nutr. 2006;46:101-123. View abstract.
  58. Glauser, T., Bircher, A., and Wuthrich, B. [Allergic rhinoconjunctivitis caused by the dust of green coffee beans]. Schweiz.Med.Wochenschr. 8-29-1992;122:1279-1281. View abstract.
  59. Gonthier, M. P., Verny, M. A., Besson, C., Remesy, C., and Scalbert, A. Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats. J.Nutr. 2003;133:1853-1859. View abstract.
  60. Olthof, M. R., Hollman, P. C., Buijsman, M. N., van Amelsvoort, J. M., and Katan, M. B. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J.Nutr. 2003;133:1806-1814. View abstract.
  61. Moridani, M. Y., Scobie, H., and O'Brien, P. J. Metabolism of caffeic acid by isolated rat hepatocytes and subcellular fractions. Toxicol.Lett. 7-21-2002;133(2-3):141-151. View abstract.
  62. Daglia, M., Tarsi, R., Papetti, A., Grisoli, P., Dacarro, C., Pruzzo, C., and Gazzani, G. Antiadhesive effect of green and roasted coffee on Streptococcus mutans' adhesive properties on saliva-coated hydroxyapatite beads. J.Agric.Food Chem. 2-27-2002;50:1225-1229. View abstract.
  63. Richelle, M., Tavazzi, I., and Offord, E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J.Agric.Food Chem. 2001;49:3438-3442. View abstract.
  64. Couteau, D., McCartney, A. L., Gibson, G. R., Williamson, G., and Faulds, C. B. Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid. J.Appl.Microbiol. 2001;90:873-881. View abstract.
  65. Daglia, M., Papetti, A., Gregotti, C., Berte, F., and Gazzani, G. In vitro antioxidant and ex vivo protective activities of green and roasted coffee. J.Agric.Food Chem. 2000;48:1449-1454. View abstract.
  66. Herling, A. W., Burger, H., Schubert, G., Hemmerle, H., Schaefer, H., and Kramer, W. Alterations of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats. Eur.J.Pharmacol. 12-10-1999;386:75-82. View abstract.
  67. Bassoli, B. K., Cassolla, P., Borba-Murad, G. R., Constantin, J., Salgueiro-Pagadigorria, C. L., Bazotte, R. B., da Silva, R. S., and de Souza, H. M. Chlorogenic acid reduces the plasma glucose peak in the oral glucose tolerance test: effects on hepatic glucose release and glycaemia. Cell Biochem.Funct. 2008;26:320-328. View abstract.
  68. Almeida, A. A., Farah, A., Silva, D. A., Nunan, E. A., and Gloria, M. B. Antibacterial activity of coffee extracts and selected coffee chemical compounds against enterobacteria. J Agric.Food Chem 11-15-2006;54:8738-8743. View abstract.
  69. Jeppesen, U., Loft, S., Poulsen, H. E., and Brsen, K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-222. View abstract.
  70. Dimaio, V. J. and Garriott, J. C. Lethal caffeine poisoning in a child. Forensic Sci. 1974;3:275-278. View abstract.
  71. Alstott, R. L., Miller, A. J., and Forney, R. B. Report of a human fatality due to caffeine. J.Forensic Sci. 1973;18:135-137. View abstract.
  72. Orozco-Gregorio, H., Mota-Rojas, D., Bonilla-Jaime, H., Trujillo-Ortega, M. E., Becerril-Herrera, M., Hernandez-Gonzalez, R., and Villanueva-Garcia, D. Effects of administration of caffeine on metabolic variables in neonatal pigs with peripartum asphyxia. Am.J Vet.Res. 2010;71:1214-1219. View abstract.
  73. Clausen, T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam.Clin Pharmacol 2010;24:595-605. View abstract.
  74. Ernest, D., Chia, M., and Corallo, C. E. Profound hypokalaemia due to Nurofen Plus and Red Bull misuse. Crit Care Resusc. 2010;12:109-110. View abstract.
  75. Banko, L. T., Haq, S. A., Rainaldi, D. A., Klem, I., Siegler, J., Fogel, J., Sacchi, T. J., and Heitner, J. F. Incidence of caffeine in serum of patients undergoing dipyridamole myocardial perfusion stress test by an intensive versus routine caffeine history screening. Am.J Cardiol. 5-15-2010;105:1474-1479. View abstract.
  76. Rigato, I., Blarasin, L., and Kette, F. Severe hypokalemia in 2 young bicycle riders due to massive caffeine intake. Clin J Sport Med. 2010;20:128-130. View abstract.
  77. Thelander, G., Jonsson, A. K., Personne, M., Forsberg, G. S., Lundqvist, K. M., and Ahlner, J. Caffeine fatalities--do sales restrictions prevent intentional intoxications? Clin Toxicol.(Phila) 2010;48:354-358. View abstract.
  78. Buscemi, S., Verga, S., Batsis, J. A., Donatelli, M., Tranchina, M. R., Belmonte, S., Mattina, A., Re, A., and Cerasola, G. Acute effects of coffee on endothelial function in healthy subjects. Eur.J Clin Nutr. 2010;64:483-489. View abstract.
  79. Rudolph, T. and Knudsen, K. A case of fatal caffeine poisoning. Acta Anaesthesiol.Scand 2010;54:521-523. View abstract.
  80. Simmonds, M. J., Minahan, C. L., and Sabapathy, S. Caffeine improves supramaximal cycling but not the rate of anaerobic energy release. Eur.J Appl Physiol 2010;109:287-295. View abstract.
  81. Moisey, L. L., Robinson, L. E., and Graham, T. E. Consumption of caffeinated coffee and a high carbohydrate meal affects postprandial metabolism of a subsequent oral glucose tolerance test in young, healthy males. Br.J Nutr. 2010;103:833-841. View abstract.
  82. MacKenzie, T., Comi, R., Sluss, P., Keisari, R., Manwar, S., Kim, J., Larson, R., and Baron, J. A. Metabolic and hormonal effects of caffeine: randomized, double-blind, placebo-controlled crossover trial. Metabolism 2007;56:1694-1698. View abstract.
  83. van Dam, R. M. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc.Dis. 2006;16:69-77. View abstract.
  84. Smits, P., Temme, L., and Thien, T. The cardiovascular interaction between caffeine and nicotine in humans. Clin Pharmacol Ther 1993;54:194-204. View abstract.
  85. Bryant, C. M., Dowell, C. J., and Fairbrother, G. Caffeine reduction education to improve urinary symptoms. Br.J.Nurs. 4-25-2002;11:560-565. View abstract.
  86. Arya, L. A., Myers, D. L., and Jackson, N. D. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet.Gynecol. 2000;96:85-89. View abstract.
  87. Jia H, Xu A, Yuan J, et al. Experimental study on cytochrome P450 enzymes after receiving ferment powder caterpillar fungus. Zhongguo Zhong Yao Za Zhi 2009;34:2079-82. View abstract.
  88. Joeres R, Richter E. Mexiletine and caffeine elimination. N Engl J Med 1987;317:117. View abstract.
  89. Zelenitsky SA, Norman A, Nix DE. The effects of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. J Infect Dis Pharmacother 1995;1:1-11.
  90. Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther 1991;50:529-37. View abstract.
  91. Broughton LJ, Rogers HJ. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol 1981;12:155-9. View abstract.
  92. Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol 1991:29:133-8. View abstract.
  93. Zhang LL, Zhang JR, Guo K, et al. Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci 2011;90:99-105. View abstract.
  94. Harder S, Staib AH, Beer C, et al. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 1988;35:651-6. View abstract.
  95. Azcona O, Barbanoi MJ, Torrent J, Jane F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol 1995;40:393-400. View abstract.
  96. Liu, T. T. and Liau, J. Caffeine increases the linearity of the visual BOLD response. Neuroimage. 2-1-2010;49:2311-2317. View abstract.
  97. Ursing, C., Wikner, J., Brismar, K., and Rojdmark, S. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J.Endocrinol.Invest 2003;26:403-406. View abstract.
  98. Hartter, S., Nordmark, A., Rose, D. M., Bertilsson, L., Tybring, G., and Laine, K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br.J.Clin.Pharmacol. 2003;56:679-682. View abstract.
  99. Zheng, J., Chen, B., Jiang, B., Zeng, L., Tang, Z. R., Fan, L., and Zhou, H. H. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res 2010;33:243-246. View abstract.
  100. Chen, Y., Xiao, C. Q., He, Y. J., Chen, B. L., Wang, G., Zhou, G., Zhang, W., Tan, Z. R., Cao, S., Wang, L. P., and Zhou, H. H. Genistein alters caffeine exposure in healthy female volunteers. Eur.J Clin.Pharmacol. 2011;67:347-353. View abstract.
  101. Gorski, J. C., Huang, S. M., Pinto, A., Hamman, M. A., Hilligoss, J. K., Zaheer, N. A., Desai, M., Miller, M., and Hall, S. D. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75:89-100. View abstract.
  102. Norager, C. B., Jensen, M. B., Weimann, A., and Madsen, M. R. Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf) 2006;65:223-228. View abstract.
  103. Daniel, W. A., Syrek, M., Rylko, Z., and Kot, M. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol.J Pharmacol 2001;53:615-621. View abstract.
  104. Wojcikowski, J. and Daniel, W. A. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study. Pharmacol Rep. 2009;61:851-858. View abstract.
  105. Gasior, M., Swiader, M., Przybylko, M., Borowicz, K., Turski, W. A., Kleinrok, Z., and Czuczwar, S. J. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice. Eur.J Pharmacol 7-10-1998;352(2-3):207-214. View abstract.
  106. Vaz, J., Kulkarni, C., David, J., and Joseph, T. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. Indian J.Exp.Biol. 1998;36:112-114. View abstract.
  107. Chroscinska-Krawczyk, M., Jargiello-Baszak, M., Walek, M., Tylus, B., and Czuczwar, S. J. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol.Rep. 2011;63:12-18. View abstract.
  108. Luszczki, J. J., Zuchora, M., Sawicka, K. M., Kozinska, J., and Czuczwar, S. J. Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. Pharmacol Rep. 2006;58:652-659. View abstract.
  109. Jankiewicz, K., Chroscinska-Krawczyk, M., Blaszczyk, B., and Czuczwar, S. J. [Caffeine and antiepileptic drugs: experimental and clinical data]. Przegl.Lek. 2007;64:965-967. View abstract.
  110. Gasior, M., Borowicz, K., Buszewicz, G., Kleinrok, Z., and Czuczwar, S. J. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Epilepsia 1996;37:262-268. View abstract.
  111. Fuhr, U., Strobl, G., Manaut, F., Anders, E. M., Sorgel, F., Lopez-de-Brinas, E., Chu, D. T., Pernet, A. G., Mahr, G., Sanz, F., and . Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol.Pharmacol. 1993;43:191-199. View abstract.
  112. Stille, W., Harder, S., Mieke, S., Beer, C., Shah, P. M., Frech, K., and Staib, A. H. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J.Antimicrob.Chemother. 1987;20:729-734. View abstract.
  113. Staib, A. H., Stille, W., Dietlein, G., Shah, P. M., Harder, S., Mieke, S., and Beer, C. Interaction between quinolones and caffeine. Drugs 1987;34 Suppl 1:170-174. View abstract.
  114. Kynast-Gales SA, Massey LK. Effect of caffeine on circadian excretion of urinary calcium and magnesium. J Am Coll Nutr. 1994;13:467-72. View abstract.
  115. Irwin PL, King G, Hicks KB. Polymerized cyclomaltoheptaose (beta-cyclodextrin, beta-CDn) inclusion complex formation with chlorogenic acid: solvent effects on thermochemistry and enthalpy-entropy compensation. Carbohydr Res. 1996 Feb 28;282:65-79. View abstract.
  116. Irwin PL, Pfeffer PE, Doner LW, et al. Binding geometry, stoichiometry, and thermodynamics of cyclomalto-oligosaccharide (cyclodextrin) inclusion complex formation with chlorogenic acid, the major substrate of apple polyphenol oxidase. Carbohydr Res. 1994 Mar 18;256:13-27. View abstract.
  117. Moreira DP, Monteiro MC, Ribeiro-Alves M, et al. Contribution of chlorogenic acids to the iron-reducing activity of coffee beverages. J Agric Food Chem. 2005 Mar 9;53:1399-402. View abstract.
  118. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr 1999;81:289-95. View abstract.
  119. van Rooij J, van der Stegen GH, Schoemaker RC, et al. A placebo-controlled parallel study of the effect of two types of coffee oil on serum lipids and transaminases: identification of chemical substances involved in the cholesterol-raising effect of coffee. Am J Clin Nutr. 1995 Jun;61:1277-83. View abstract.
  120. - Jackson, L. S. and Lee, K. Chemical forms of iron, calcium, magnesium and zinc in coffee and rat diets containing coffee. J-Food-Prot.Ames, Iowa : International Association of Milk, Food, and Environmental Sanitarians 1988;51:883-886.
  121. Pereira MA, Parker ED, and Folsom AR. Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28 812 postmenopausal women. Arch Intern Med. 2006 Jun 26;166:1311-6. View abstract.
  122. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr. 2003 Oct;78:728-33. View abstract.
  123. Keijzers GB, De Galan BE, Tack CJ, et al. Caffeine can decrease insulin sensitivity in humans. Diabetes Care. 2002 Feb;25:364-9. View abstract.
  124. Greer F, Hudson R, Ross R, et al. Caffeine ingestion decreases glucose disposal during a hyperinsulinemic-euglycemic clamp in sedentary humans. Diabetes. 2001 Oct;50:2349-54. View abstract.
  125. Thong FS and Graham TE. Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans. J Appl Physiol . 2002 Jun;92:2347-52. View abstract.
  126. Suzuki A, Kagawa D, Ochiai R, et al. Green coffee bean extract and its metabolites have a hypotensive effect in spontaneously hypertensive rats. Hypertens Res. 2002 Jan;25:99-107. View abstract.
  127. Blum J, Lemaire B, and Lafay S. Effect of a green decaffeinated coffee extract on glycaemia: a pilot prospective study. Nutrafoods 2007;6:13-17.
  128. Yamaguchi T, Chikama A, Mori K, et al. Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis. 2008 Jul;18:408-14. View abstract.
  129. Olthol MR, Hollman PCH, Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans. J Nutr 2001;131:66-71. View abstract.
  130. Vinson JA, Burnham BR, Nagendran MV. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes 2012;5:21-7. [RETRACTED]. View abstract.
  131. Dellalibera O, Lemaire B, Lafay S. Svetol, green coffee extract, induces weight loss and increases the lean to fat mass ratio in volunteers with overweight problem. Phytotherapie 2006;4:194-7.
  132. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res 2007;35:900-8. View abstract.
  133. Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract 2011;2011. pii: 382852. Epub 2010 Aug 31. View abstract.
  134. Alonso-Salces RM, Serra F, Reniero F, Héberger K. Botanical and geographical characterization of green coffee (Coffea arabica and Coffea canephora): chemometric evaluation of phenolic and methylxanthine contents. J Agric Food Chem 2009;57:4224-35. View abstract.
  135. Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med 2006;6:9. View abstract.
  136. Farah A, Donangelo CM. Phenolic compounds in coffee. Braz J Plant Physiol 2006;18:23-36.
  137. Farah A, Monteiro M, Donangelo CM, Lafay S. Chlorogenic acids from green coffee extract are highly bioavailable in humans. J Nutr 2008;138:2309-15. View abstract.
  138. Watanabe T, Arai Y, Mitsui Y, et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens 2006;28:439-49. View abstract.
  139. Kozuma K, Tsuchiya S, Kohori J, et al. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertens Res. 2005 Sep;28:711-8. View abstract.
  140. Ochiai R, Jokura H, Suzuki A, et al. Green coffee bean extract improves human vasoreactivity. Hypertens Res 2004;27:731-7. View abstract.
  141. Duncan L. The green coffee bean that burns fat fast. The Dr. Oz Show, April 25, 2012. Available at: http://www.doctoroz.com/blog/lindsey-duncan-nd-cn/green-coffee-bean-burns-fat-fast.
  142. Lake CR, Rosenberg DB, Gallant S, et al. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990;47:675-85. View abstract.
  143. Forrest WH Jr, Bellville JW, Brown BW Jr. The interaction of caffeine with pentobarbital as a nighttime hypnotic. Anesthesiology 1972;36:37-41. View abstract.
  144. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004;94:13-8. View abstract.
  145. Watson JM, Sherwin RS, Deary IJ, et al. Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use. Clin Sci (Lond) 2003;104:447-54. View abstract.
  146. Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005;294:2330-5. View abstract.
  147. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004;176:1-29. View abstract.
  148. Anderson BJ, Gunn TR, Holford NH, Johnson R. Caffeine overdose in a premature infant: clinical course and pharmacokinetics. Anaesth Intensive Care 1999;27:307-11. View abstract.
  149. Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J Toxicol Clin Toxicol 1988;26:407-15. View abstract.
  150. Benowitz NL, Osterloh J, Goldschlager N, et al. Massive catecholamine release from caffeine poisoning. JAMA 1982;248:1097-8. View abstract.
  151. Haller CA, Benowitz NL, Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005;118:998-1003.. View abstract.
  152. Petrie HJ, Chown SE, Belfie LM, et al. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 2004;80:22-8. View abstract.
  153. Lane JD, Barkauskas CE, Surwit RS, Feinglos MN. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 2004;27:2047-8. View abstract.
  154. Durrant KL. Known and hidden sources of caffeine in drug, food, and natural products. J Am Pharm Assoc 2002;42:625-37. View abstract.
  155. Beach CA, Mays DC, Guiler RC, et al. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther 1986;39:265-70. View abstract.
  156. Dews PB, O'Brien CP, Bergman J. Caffeine: behavioral effects of withdrawal and related issues. Food Chem Toxicol 2002;40:1257-61. View abstract.
  157. Holmgren P, Norden-Pettersson L, Ahlner J. Caffeine fatalities--four case reports. Forensic Sci Int 2004;139:71-3. View abstract.
  158. Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington, DC: National Academy Press, 2001. Available at: http://books.nap.edu/books/0309082587/html/index.html.
  159. Zheng XM, Williams RC. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole Tl myocardial perfusion imaging. J Nucl Med Technol 2002;30:123-7. View abstract.
  160. Aqel RA, Zoghbi GJ, Trimm JR, et al. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol 2004;93:343-6. View abstract.
  161. Underwood DA. Which medications should be held before a pharmacologic or exercise stress test? Cleve Clin J Med 2002;69:449-50. View abstract.
  162. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002;40:1243-55. View abstract.
  163. Stanek EJ, Melko GP, Charland SL. Xanthine interference with dipyridamole-thallium-201 myocardial imaging. Pharmacother 1995;29:425-7. View abstract.
  164. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000;39:127-53. View abstract.
  165. Wahllander A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989;37:279-83. View abstract.
  166. Sanderink GJ, Bournique B, Stevens J, et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. Pharmacol Exp Ther 1997;282:1465-72. View abstract.
  167. Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther 1991;50:363-71. View abstract.
  168. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8. View abstract.
  169. May DC, Jarboe CH, VanBakel AB, Williams WM. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 1982;31:656-61. View abstract.
  170. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98. View abstract.
  171. Nawrot P, Jordan S, Eastwood J, et al. Effects of caffeine on human health. Food Addit Contam 2003;20:1-30. View abstract.
  172. Massey LK, Whiting SJ. Caffeine, urinary calcium, calcium metabolism and bone. J Nutr 1993;123:1611-4. View abstract.
  173. Infante S, Baeza ML, Calvo M, et al. Anaphylaxis due to caffeine. Allergy 2003;58:681-2. View abstract.
  174. Nix D, Zelenitsky S, Symonds W, et al. The effect of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects. Clin Pharmacol Ther 1992;51:183.
  175. Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy 2001;21:647-51.. View abstract.
  176. Massey LK. Is caffeine a risk factor for bone loss in the elderly? Am J Clin Nutr 2001;74:569-70. View abstract.
  177. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289:1537-45.. View abstract.
  178. Bara AI, Barley EA. Caffeine for asthma. Cochrane Database Syst Rev 2001;4:CD001112.. View abstract.
  179. Horner NK, Lampe JW. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J Am Diet Assoc 2000;100:1368-80. View abstract.
  180. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33:1399-403. View abstract.
  181. Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. Ann Pharmacother 2002;36:992-5.. View abstract.
  182. Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The Rancho Bernardo Study. Am J Epidemiol 1996:144:642-4. View abstract.
  183. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73:532-8. View abstract.
  184. Klag MJ, Wang NY, Meoni LA, et al. Coffee intake and risk of hypertension: The John Hopkins precursors study. Arch Intern Med 2002;162:657-62. View abstract.
  185. Samarrae WA, Truswell AS. Short-term effect of coffee on blood fibrinolytic activity in healthy adults. Atherosclerosis 1977;26:255-60. View abstract.
  186. Ardlie NG, Glew G, Schultz BG, Schwartz CJ. Inhibition and reversal of platelet aggregation by methyl xanthines. Thromb Diath Haemorrh 1967;18:670-3. View abstract.
  187. Ali M, Afzal M. A potent inhibitor of thrombin stimulated platelet thromboxane formation from unprocessed tea. Prostaglandins Leukot Med 1987;27:9-13. View abstract.
  188. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8. View abstract.
  189. Sinclair CJ, Geiger JD. Caffeine use in sports. A pharmacological review. J Sports Med Phys Fitness 2000;40:71-9. View abstract.
  190. Lloyd T, Johnson-Rollings N, Eggli DF, et al. Bone status among postmenopausal women with different habitual caffeine intakes: a longitudinal investigation. J Am Coll Nutr 2000;19:256-61. View abstract.
  191. Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000;23:455-9. View abstract.
  192. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000;49:59-63. View abstract.
  193. Williams MH, Branch JD. Creatine supplementation and exercise performance: an update. J Am Coll Nutr 1998;17:216-34. View abstract.
  194. Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001;25:316-24. View abstract.
  195. Dews PB, Curtis GL, Hanford KJ, O'Brien CP. The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 1999;39:1221-32. View abstract.
  196. Nurminen ML, Niittynen L, Korpela R, Vapaatalo H. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 1999;53:831-9. View abstract.
  197. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-40. View abstract.
  198. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694-700. View abstract.
  199. Chiu KM. Efficacy of calcium supplements on bone mass in postmenopausal women. J Gerontol A Biol Sci Med Sci 1999;54:M275-80. View abstract.
  200. Vandeberghe K, Gillis N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996;80:452-7. View abstract.
  201. Wallach J. Interpretation of Diagnostic Tests. A synopsis of Laboratory Medicine. Fifth ed; Boston, MA: Little Brown, 1992.
  202. Hodgson JM, Puddey IB, Burke V, et al. Effects on blood pressure of drinking green and black tea. J Hypertens 1999;17:457-63. View abstract.
  203. Wakabayashi K, Kono S, Shinchi K, et al. Habitual coffee consumption and blood pressure: A study of self-defense officials in Japan. Eur J Epidemiol 1998;14:669-73. View abstract.
  204. Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for bodybuilding. J Neurol Neurosurg Psychiatr 2000;68:112-3. View abstract.
  205. Joeres R, Klinker H, Heusler H, et al. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987;33:163-9. View abstract.
  206. Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J Clin Psychiatry 1988;49:72-3. View abstract.
  207. Mester R, Toren P, Mizrachi I, et al. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry 1995;37:348-50. View abstract.
  208. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989;33:474-8. View abstract.
  209. Carbo M, Segura J, De la Torre R, et al. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther 1989;45:234-40. View abstract.
  210. Harder S, Fuhr U, Staib AH, Wolff T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989;87:89S-91S. View abstract.
  211. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Last reviewed - 10/09/2023